Gain Therapeutics to present long-term Phase 1b extension data for rexaceract at MDS Congress
The company said it will present long-term open-label Phase 1b extension data for rexaceract on Oct. 7, 2026, covering dosing for up to 12 months in Parkinson’s patients with or without a GBA1 mutation.